NCT03999229 is a Phase 1 clinical trial of SNO in Transfusion Related Complication, sponsored by James Reynolds.

Who is sponsoring NCT03999229?

NCT03999229 is sponsored by James Reynolds.

What drugs are being tested in NCT03999229?

Interventions in NCT03999229: SNO, Normal Saline, Red Blood Cell.

What condition does NCT03999229 study?

NCT03999229 studies Transfusion Related Complication.

Is NCT03999229 still recruiting?

NCT03999229 is currently recruiting now. Last updated 2 December 2025.

Last reviewed 2025-12-02 · How we verify

NCT03999229

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion

Recruiting now Phase 1 Last updated 2 December 2025

What this trial tests

Phase 1 trial testing SNO in Transfusion Related Complication in 35 participants. Currently enrolling.

Timeline

25 July 2019

Primary endpoint
29 February 2028

29 February 2028

Quick facts

Lead sponsor	James Reynolds
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	25 July 2019
Primary completion	29 February 2028
Estimated completion	29 February 2028
Sites	1 location across United States

Drugs / interventions tested

SNO — full drug profile →
Normal Saline
Red Blood Cell — full drug profile →

Conditions studied

Transfusion Related Complication — all drugs for Transfusion Related Complication →

Sponsor

James Reynolds — full company profile →

Who can join

Adults 18 to 35, any sex, with Transfusion Related Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Purpose of the study is to test the hypothesis that administration of an S-nitrosylating (SNO) agent can improve tissue oxygenation during transfusion of packed red blood cells (RBCs).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Renal dysfunction in adults following cardiopulmonary bypass is linked to declines in S-nitroso hemoglobin: a case series.
Moyal A, Nazemian R, Colon EP, Zhu L, et al · · 2024 · cited 3× · PMID 38694342 · DOI 10.1097/ms9.0000000000001880

Verify or expand the search:

Other trials of SNO

Trials testing the same drug.

NCT04528771 — S-Nitrosylation Therapy of COVID-19 · EARLY_PHASE1 · withdrawn

Other recruiting trials for Transfusion Related Complication

Currently open trials in the same condition.

NCT06399536 — Individualized ANH for Non-cardiac Surgery · NA · recruiting
NCT05806346 — Goal-directed vs. Empirical Tranexamic Acid Administrationin Cardiovascular Surgery · NA · recruiting
NCT06403163 — Transfusion Surveillance in Anaesthesia · recruiting

Other James Reynolds trials

Trials by the same sponsor.

NCT04528771 — S-Nitrosylation Therapy of COVID-19 · EARLY_PHASE1 · withdrawn
NCT03926741 — GSNOR Phenotyping/GSNO Challenge in Severe Asthma · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03999229 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by James Reynolds
Last refreshed: 2 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03999229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing